NoLimitStock.com brings you the most fascinating reviews and research reports about the most active Biotech stocks VALE, ARNA, BIIB, GALE
Pompano Beach, FL -- (SBWIRE) -- 01/03/2013 -- Biotechnology sector was among the bullish moving sector of the day with positive change of +0.16% at 12:56 am supporting the broader healthcare sector which was moving up +0.20%.
Among the biotech movers, few most actively traded stocks with leading volumes on Thursday included Biogen Idec Inc. (NASDAQ:BIIB), Galena Biopharma (NASDAQ:GALE) and Arena (NASDAQ:ARNA).
Biogen (BIIB) stock was finding its way above the trend line as an experimental drug to fight against amyotrophic lateral sclerosis, normally called Lou Gehrig's disease in the United States, failed to show efficacy in a crucial trial and Biogen Idec stated that it would halt creation of the cure.
What was pushing down Biogen Stock in bearish claws? Find in this report
The drug, dexpramipexole, had revealed promise and looked to combat against ALS in a mid-stage clinical trial in 2011, creating a chance for patients suffering from the progressive, deadly disease, who presently have lesser options.
In separate news Piper Jaffray began coverage on stock of Galena Biopharma (NASDAQ: GALE) in a research note given to investors on Monday. The firm gave an overweight rating and a kept target price of $2.50 on the stock.
What Experts have got for Galena Biopharma stock? Get results here
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares were trading just below the trend line on Thursday as the company declared this week that the it is ready to present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013, at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) at The Westin St. Francis in San Francisco, California. Jack Lief, Arena's President and Chief Executive Officer, is slated to give a corporate summary to audience.
Can Arena please investors at its upcoming conference? Find out here
VIVUS (NASDAQ:VVUS) was trading bullishly on Thursday with strong volume on the board as the recurrence of obesity drugs following over a decade has received passionate investor focus.
VIVUS (NASDAQ:VVUS) and Arena Pharmaceuticals (NASDAQ:ARNA) led the tables and spent most of the year in this way. VIVUS' Qsymia turned into the primary drug to the market, but its unenthusiastic initial performance put sold water on raging market confidence.
How VIVUS cheered up investors in 2012? Find out here
About No Limit Stocks
NOLIMITSTOCKS.com is made up of a team of professional analyst that possess over 30 years of expert, stock market experience. Our goal is to research thousands of companies and provide investors with the latest insights in the market with stocks that can make explosive profits. We study the hottest companies so you don't have to!
Our newsletter is always free to Join and offers a variety of useful investors tools that will help you break the limits! There will be no regrets!
The assembled information disseminated by nolimitstocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. nolimitstocks.com does expect that investors will buy and sell securities based on information assembled and presented in nolimitstocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)